Acute interstitial pneumonia
Updates to Article Attributes
Acute interstitial pneumonitis (AIP), isalso know as Hamman-Rich syndrome is a rapidly progressive non infectiousinterstitial lung disease of unknown aetiology. It is considered the only acute process of the idiopathic intersitial pneumonias.
Epidemiology
AIP tends to occur in those without pre-existing lung disease and typically affects middle age adults (mean~ 50 years 5).
Clinical presentation
Clinical features are varied. Patients often have a history of an antecedent prior illness such as a viral viral upper respiratory infection. Common initial symptoms include myalgias, arthralgias, pyrexia, chills, and malaise. Severe exertional dyspnoea develops over a matter of days to weeks 13.
Pathology
AIP is characterised histologically by histologically by diffuse alveolar damage (DAD) 2. The alveolar damage comprises of three three phases:
- acute exudative phase
- subsequent organising phase
- final
fibroticfibrotic phase
Histological features are very similar with that of the adult respiratory distress syndrome (ARDS).
Radiographic features
The correct clinical context is vital for image interpretation.
Plain film
Non specific and often shows bilateral patchy airspace opacification.
HRCT
During the initial stages stages AIP can can have similar features to adult respiratory distress syndrome (ARDS).
Features include:
- areas with ground-glass attenuation: generally tends to be bilateral and symmetrical 10
- traction bronchiectasis: can be seen in ~80% of cases during the course of the disease 4 and correlates with disease duration 2
- lung parechymal architectural distortion
- air space consolidation: may have a slight predilection towards the dependent portions 5
Treatment and prognosis
The condition usually usually progresses to respiratory failure that requires mechanical ventilation and corticosteroid therapy. Even despite mechanical ventilation, it often tends to carry a grave grave prognosis with > 70% mortality at ~ 3 months 1,
History and etymology
- clinical features first described by L Hamman andA Rich in
19351935 8 - pathological processes first described by A L Katzenstein et al in 1986 3
Differential diagnosis
Considerations in early stages include
- adult respiratory distress syndrome (ARDS): can have other organ involvement 9
- infectious multifocal pneumonia
For a more general differential, consider
-<p><strong>Acute interstitial pneumonitis (AIP)</strong> is a rapidly progressive non infectious <a href="/articles/interstitial-lung-disease">interstitial lung disease</a> of unknown aetiology. It is considered the only acute process of the <a href="/articles/idiopathic-interstitial-pneumonias">idiopathic intersitial pneumonias</a>.</p><h4>Epidemiology</h4><p>AIP tends to occur in those without pre-existing lung disease and typically affects middle age adults (mean ~ 50 years <sup>5</sup>).</p><h4>Clinical presentation</h4><p>Clinical features are varied. Patients often have a history of an antecedent prior illness such as a viral upper respiratory infection. Common initial symptoms include myalgias, arthralgias, pyrexia, chills, and malaise. Severe exertional dyspnoea develops over a matter of days to weeks <sup>13</sup>. </p><h4>Pathology</h4><p>AIP is characterised histologically by <a href="/articles/diffuse-alveolar-damage">diffuse alveolar damage (DAD)</a> <sup>2</sup>. The alveolar damage comprises of three phases:</p><ul>- +<p><strong>Acute interstitial pneumonitis (AIP), </strong>also know as <strong>Hamman-Rich syndrome</strong> is a rapidly progressive non infectious <a href="/articles/interstitial-lung-disease">interstitial lung disease</a> of unknown aetiology. It is considered the only acute process of the <a href="/articles/idiopathic-interstitial-pneumonias">idiopathic intersitial pneumonias</a>.</p><h4>Epidemiology</h4><p>AIP tends to occur in those without pre-existing lung disease and typically affects middle age adults (mean ~ 50 years <sup>5</sup>).</p><h4>Clinical presentation</h4><p>Clinical features are varied. Patients often have a history of an antecedent prior illness such as a viral upper respiratory infection. Common initial symptoms include myalgias, arthralgias, pyrexia, chills, and malaise. Severe exertional dyspnoea develops over a matter of days to weeks <sup>13</sup>.</p><h4>Pathology</h4><p>AIP is characterised histologically by <a href="/articles/diffuse-alveolar-damage">diffuse alveolar damage (DAD)</a> <sup>2</sup>. The alveolar damage comprises of three phases:</p><ul>
-<li>final fibrotic phase</li>-</ul><p>Histological features are very similar with that of the <a href="/articles/adult-respiratory-distress-syndrome">adult respiratory distress syndrome (ARDS)</a>.</p><h4>Radiographic features</h4><p>The correct clinical context is vital for image interpretation.</p><h5>Plain film</h5><p>Non specific and often shows bilateral patchy <a href="/articles/air-space-opacification-1">airspace opacification</a>.</p><h5>HRCT</h5><p>During the initial stages AIP can have similar features to <a href="/articles/adult-respiratory-distress-syndrome">adult respiratory distress syndrome (ARDS)</a>. </p><p>Features include</p><ul>- +<li>final fibrotic phase</li>
- +</ul><p>Histological features are very similar with that of the <a href="/articles/acute-respiratory-distress-syndrome-1">adult respiratory distress syndrome (ARDS)</a>.</p><h4>Radiographic features</h4><p>The correct clinical context is vital for image interpretation.</p><h5>Plain film</h5><p>Non specific and often shows bilateral patchy <a href="/articles/air-space-opacification-1">airspace opacification</a>.</p><h5>HRCT</h5><p>During the initial stages AIP can have similar features to <a href="/articles/acute-respiratory-distress-syndrome-1">adult respiratory distress syndrome (ARDS)</a>.</p><p>Features include:</p><ul>
-</ul><h4>Treatment and prognosis</h4><p>The condition usually progresses to respiratory failure that requires mechanical ventilation and corticosteroid therapy. Even despite mechanical ventilation, it often tends to carry a grave prognosis with > 70% mortality at ~ 3 months <sup>1,</sup></p><h4>History and etymology</h4><ul>-<li>clinical features first described by <strong>L Hamman</strong> and <strong>A Rich</strong> in 1935 <sup>8</sup>- +</ul><h4>Treatment and prognosis</h4><p>The condition usually progresses to respiratory failure that requires mechanical ventilation and corticosteroid therapy. Even despite mechanical ventilation, it often tends to carry a grave prognosis with > 70% mortality at ~ 3 months <sup>1,</sup></p><h4>History and etymology</h4><ul>
- +<li>clinical features first described by <strong>L Hamman</strong> and <strong>A Rich</strong> in 1935 <sup>8</sup>
-<a href="/articles/adult-respiratory-distress-syndrome">adult respiratory distress syndrome (ARDS)</a>: can have other organ involvement <sup>9</sup> </li>- +<a href="/articles/acute-respiratory-distress-syndrome-1">adult respiratory distress syndrome (ARDS)</a>: can have other organ involvement <sup>9</sup>
- +</li>